The Premier Consulting Blog

NOVEMBER 20, 2023

Clinical development experts would need to navigate the potential complexities arising from this regulatory shift, particularly in terms of trial design and evidence generation. years after publication; no earlier than October 1, 2027) End of Enforcement Discretion for: Premarket review for high-risk IVDs. Phase 4 (3.5

Laboratories 52

Laboratories FDA Clinical Development Regulations 52

Agency IQ

FEBRUARY 15, 2024

These topics include administrative, advanced manufacturing, the Animal Rule, antimicrobials, biosimilars, blood products, breakthrough devices, cell and gene therapy products, CGMP, clinical pharmacology, clinical trials, clinical/medical guidance, combination products, communication, compounding, cybersecurity, device software, digital health technologies, (..)

FDA 40

FDA Science Biosimilars Clinical Trials 40

Codon

OCTOBER 6, 2024

Results such as these have been so encouraging that in September of last year, the FDA began to review the idea of moving to human trials. Indeed, the stakes in the first real-world use of artificial wombs may be higher than in almost any clinical trial imaginable.

FDA 89

FDA Hospitals Engineering Research 89

The Pharma Data

DECEMBER 30, 2020

The company’s product candidate is targeting the global metastatic cancer treatment market, projected to be worth $111.2 billion by 2027. based partner NeuroRx concluded enrollment of the Phase IIb/III trial of Zyesami (previously RLF-100 TM : aviptadil) for the treatment of Respiratory Failure in patients with Critical COVID-19.

Immune Response 52

Immune Response Vaccine Clinical Trials Treatment 52

The Pharma Data

MAY 4, 2021

and developed Europe following the approvals in 2019 for combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced renal cell carcinoma; as well as. RE47,739 for Ibrance by more than four years until March 2027. In February 2021, Pfizer announced that the U.S.

Vaccine 40

Vaccine Production FDA Clinical Trials 40

Agency IQ

FEBRUARY 21, 2024

In sum, the aim of the organization and its stakeholders is to develop an online environment to house everything from clinical trial data to marketing applications, to product labeling, manufacturing changes, and more.

Science 40

Science Regulations International FDA 40

Agency IQ

JULY 28, 2023

September 30, 2023 PDUFA Digital Health Technologies Establish a secure cloud technology to enhance its infrastructure and analytics environment that will enable FDA to effectively receive, aggregate, store, and process large volumes of data from trials conducted using DHTs.

FDA 40

FDA Science Biosimilars Regulations 40